公开(公告)号：WO2017072292A1

公开(公告)日：2017-05-04

申请号：PCT/EP2016/076060

申请日：2016-10-28

Applicant: RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN

Inventor： DAHL, Edgar ,  KLOTEN, Vera ,  MIJNES, Jolein

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/154

Abstract: The present invention relates in a first aspect to new methods for diagnosing or identifying breast cancer or pre-forms thereof in a subject as well as methods for monitoring the development or progress of breast cancer or pre-forms thereof in a subject and methods for the stratification of the therapeutic regimen of a subject suspected to be afflicted with breast cancer or being at risk of developing breast cancer or pre-forms thereof whereby the level or amount of methylation of at least one of the promoters selected from SPAG6-, PER1-and NKX2-6-gene in a sample of said subject is determined followed by the step of diagnosing or identifying breast cancer or pre-forms thereof based on the level on amount of methylation of the at least one promoter. Further, the present invention relates to the use of a kit in a method according to the present invention. Finally, the present invention relates to new biomarkers, namely, the promoter of the SPAG6-gene, the promoter of the PER1-gene and the promoter of the NKX2-6-gene, in particular, the level or amount of methylation of said promoters is a biomarker for breast cancer.

Abstract translation: 本发明在第一方面涉及用于诊断或鉴定受试者中的乳腺癌或其预形式的新方法，以及用于监测乳腺癌或预形成的发展或进展的方法 其用于分层怀疑患有乳腺癌或有患乳腺癌风险的受试者的治疗方案的分层方法，其中至少一种启动子的甲基化水平或量 根据所述至少一种启动子的甲基化水平确定所述受试者的样品中选自SPAG6-，PER1-和NKX2-6-基因的序列，然后进行诊断或鉴定乳腺癌或其预先形式的步骤 。 此外，本发明涉及在根据本发明的方法中使用试剂盒。 最后，本发明涉及新的生物标志物，即SPAG6基因的启动子，PER1基因的启动子和NKX2-6基因的启动子，特别是所述启动子的甲基化水平或量 是乳腺癌的生物标志物。

公开(公告)号：WO2013144362A1

公开(公告)日：2013-10-03

申请号：PCT/EP2013/056875

申请日：2013-04-02

Applicant: RWTH AACHEN

Inventor： ROSE, Michael ,  DAHL, Edgar

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/154

Abstract: The present invention relates to new methods for diagnosing or identifying bladder cancer in a subject for predicting the clinical outcome or determining the treatment course in a subject afflicted with bladder cancer as well as for the stratification of the therapeutic regimen of a subject with bladder cancer and for monitoring the progress of bladder cancer in a subject. The methods are based on the determination of the level or amount of methylation of the promoter of the ECRG4- and/or the promoter of the ITIH5-gene in a sample of said subject. In addition, the present invention relates to the use of a kit in a method according to the present invention. Finally, the present invention relates to new biomarkers, namely, the promoter of the ECRG4-gene or the promoter of the ITIH5-gene; in particular, the level or amount of methylation of said promoters as biomarkers for bladder cancer.

Abstract translation: 本发明涉及用于诊断或鉴别受试者中膀胱癌的新方法，用于预测患有膀胱癌的受试者的临床结果或确定治疗过程以及用于患有膀胱癌的受试者的治疗方案的分层，以及 用于监测受试者膀胱癌的进展。 所述方法基于所述受试者样品中ECRG4-和/或ITIH5-基因启动子的启动子的甲基化水平或量的测定。 此外，本发明涉及一种试剂盒在根据本发明的方法中的用途。 最后，本发明涉及新的生物标志物，即ECRG4基因的启动子或ITIH5基因的启动子; 特别是所述启动子作为膀胱癌生物标志物的甲基化水平或数量。

公开(公告)号：WO2010130825A2

公开(公告)日：2010-11-18

申请号：PCT/EP2010/056645

申请日：2010-05-14

Applicant: RWTH AACHEN ,  DAHL, Edgar ,  WIESMANN, Frank ,  FRANKEN, Laura

Inventor： DAHL, Edgar ,  WIESMANN, Frank ,  FRANKEN, Laura

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q1/6809 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The present invention relates to new targets for cancer therapy and / or diagnosis. In particular, the present invention provides new prophylactic and therapeutic targets and diagnostic markers for cancer, in particular solid tumours. In a first aspect, the present invention relates to methods of screening, design, engineering or otherwise producing a prophylactic or therapeutic agent for use in treatment of cancer. In a further aspect, the present invention relates to diagnostic methods as well as methods for stratification of cancer-therapy.

Abstract translation: 本发明涉及用于癌症治疗和/或诊断的新靶标。 特别地，本发明提供了用于癌症，特别是实体瘤的新的预防和治疗靶标和诊断标志物。 在第一方面，本发明涉及筛选，设计，工程化或以其他方式制备用于治疗癌症的预防或治疗剂的方法。 另一方面，本发明涉及诊断方法以及癌症治疗分层方法。